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One of the factors providing the diversity and heterogeneity of malignant tumors, particularly breast cancer, are genetic varia-
tions, due to gene polymorphism, and, especially, the phenomenon of loss of heterozygosity (LOH). It has been shown that LOH 
in some genes could be a good prognostic marker. Aim: To perform genome-wide study on LOH in association with metastasis-
free survival in breast cancer. Materials and Methods: The study involved 68 patients with breast cancer. LOH status was detected 
by microarray analysis, using a high density DNA-chip CytoScanTM HD Array (Affymetrix, USA). The Chromosome Analysis 
Suite 3.1 (Affymetrix, USA) software was used for result processing. Results: 13,815 genes were examined, in order to detect 
LOH. The frequency of LOH varied from 0% to 63%. The association analysis identified four genes: EDA2R, PGK1, TAF9B and 
CYSLTR1 that demonstrated the presence of LOH associated with metastasis-free survival (log-rank test, p < 0.03). Conclusions: 
The presence of LOH in EDA2R, TAF9B, and CYSLTR1 genes is associated with metastasis-free survival in breast cancer patients, 
indicating their potential value as prognostic markers.
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It is well known that one of the factors determining 
the individual diversity and heterogeneity of the tumor, 
including breast cancer, is a normal genetic variability 
caused by gene polymorphism (single nucleotide poly-
morphism — SNP). SNP in the tumor tissue can be mani-
fested as the phenomenon of allelic imbalance (AI). Also, 
the special case — the loss of heterozygosity (LOH) — 
is often detected. LOH is a loss (structural or functional) 
of one of the alleles of a heterozygous genotype, result-
ing in a reduced frequency of heterozygous genotypes 
compared with genomic DNA. AI is presented by allelic 
deletions (loss of one copy of the locus), duplication 
or amplification of one allele [1]. A. Knudson was the first 
to describe the phenomenon of AI in tumors in 1971. Ac-
cording to his two-hit carcinogenesis model, the inactiva-
tion of tumor suppressor genes required two successive 
mutational events — loss of one allele as a result of LOH 
and somatic mutation in the other allele. The loss of the 
allele provides the opportunity of a manifestation of lethal 
recessive mutation in the remaining allele [2, 3].
In addition, LOH and AI can lead to the activation 
of oncogenes and inactivation of tumor suppressor genes, 
which can result in uncontrolled cell growth and metastasis 
[4, 5]. Currently, allele imbalance and LOH are well explored 
and shown for many genes in different types of cancer. 
The biological meaning of LOH in carcinogenesis is sug-
gested to be associated with inactivation of heterozygous 
loci of pathogenetically significant genes, thus providing 
tumor progression, including metastasizing [6–12]. From 
perspective of breast cancer (BC), the most important 
AI and LOH were shown for cancer-related genes, such 
as the ERBB2 (HER2) [13], BRCA1 and BRCA2 [14–16]. 
Recently, a large study on LOH in BC was performed for 
the following genes: EGFR, TERT, TP53, CASP8, PARP2, 
GATA3, and BRCA1 [17]. Also, it was demonstrated that 
the LOH in telomeric sites of chromosomes in BC and ovar-
ian tumor cells appeared to be a good predictor of clinical 
course of diseases [18]. However, most studies on AI, 
especially the LOH in BC, were focused on genes, con-
tributing to malignant transformation of normal epithelial 
breast cells, but not on cancer progression [19].
Thus, the genome-wide LOH study in relation 
to cancer progression is necessary to understand its 
contribution to disease outcome and also to find new 
effective prognostic markers. In this work we per-
formed the genome-wide study on the LOH in as-
sociation with metastasis-free survival in BC patients.
MATERIALS AND METHODS
The study group. A total of 68 patients aged from 
28 to 68 years (median age 53 years) were enrolled 
in the study (Table 1). The diagnosis of BC was verified 
morphologically. The tumor stages were IIA–IIIB. In ac-
cordance with the Consensus Conference on Neo-
adjuvant Chemotherapy in Carcinoma of the Breast, 
April 26–28, 2003, Philadelphia, Pennsylvania [20], 
all patients underwent 2–4 courses of neoadjuvant 
chemotherapy (NAC) by FAC scheme (5-fluorouracil, 
doxorubicin, cyclophosphamide), CAX scheme (cy-
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clophosphamide, doxorubicin, capecitabine). Surgery 
was performed 3–5 weeks after the completion of NAC 
followed by two cycles of adjuvant chemotherapy with 
FAC regimen. Radiotherapy and/or hormonal treat-
ment were given if required.
The study was carried out in accordance with Hel-
sinki Declaration of 1964 (amended in 1975 and 1983) 
and was approved by The Ethical Committee of the 
Institute of Oncology. Signed informed consent was 
obtained from all participants.
Table 1. The clinicopathological parameters of BC patients (n = 68)
Trait Value Number of patients, n (%)
Age, years ≤ 45 21 (30.9)
> 45 47 (69.1)
Menstrual status Premenopausal 36 (52.9)
Postmenopausal 32 (47.1)
Histological type Invasive ductal carcinoma 58 (85.3)
Invasive lobular carcinoma 3 (4.4)
Medullary carcinoma 2 (2.9)
Others 5 (7.4)
Tumor size T1 9 (13.2)
T2 52 (76.5)
T3 3 (4.4)
T4 4 (5.9)
Lymph node status N0 27 (39.7)
N1 31 (45.6)
N2 4 (5.9)
N3 6 (8.8)
Estrogen receptor Positive 33 (48.5)
Negative 31 (42.6)
No data 4 (5.9)
Progesterone receptor Positive 35 (51.5)
Negative 29 (42.3)
No data 4 (5.9)
HER2 0/+ 47 (69.1)
++ 10 (14.7)
+++ 6 (8.8)
No data 5 (7.4)
Molecular subtype Luminal B 40 (59.7)
Triple negative 17 (25.4)
HER2-positive 10 (14.9)
Histological form Unicentric 45 (66.2)
Multicentric 23 (33.8)
NAC regimen CAX 28 (41.2)
FAC 40 (58.8)
DNA extraction. Biopsies of tumor tissues were 
obtained before treatment under ultrasound guidance. 
The tissues were placed in RNAlater (Ambion, USA), 
incubated for 24 h at room temperature and stored at 
–80 °С until DNA and RNA extraction.
DNA was extracted from 68 biopsy specimens 
of tumor tissues using QIAamp DNA mini Kit (Qiagen, 
Germany). DNA concentration and purity were as-
sessed using NanoDrop 2000 instrument (Thermo 
Scientific, USA). The concentration varied between 
50 to 150 ng/µl and А260/А280 and А260/А230 ratios 
were 2.10–2.35 and 2.15–2.40, respectively. The integrity 
of DNA was assessed using TapeStation instrument (Agi-
lent Technologies, USA); the fragments of the DNA were 
no longer than 48 kbp, thus suggesting its high integrity.
Microarray analysis. The CytoScanTM HD Array 
chips (Affymetrix, USA) were used. They contained 
probes for 2,670,000 markers including 1,900,000 non-
polymorphic markers for the analysis of copy number 
variations and more than 750,000 SNPs. The sample 
processing, arrays hybridization and scanning were 
performed according to the manufacturer’s protocols 
for Affymetrix GeneChip® Scanner 3000 7G. The re-
sults were analysed using Chromosome Analysis Suite 
3.1 software (Affymetrix, USA).
Statistical analysis. Statistical analysis was per-
formed using STATISTICA 8.0 software package (Stat-
Soft Inc., USA). A significance level of p < 0.05 was 
considered for statistically significant differences 
between treatment groups. p-value < 0.05 was con-
sidered statistically significant. The Kaplan — Meier 
curves were used for the analysis of overall and meta-
stasis-free survival [21]. Comparison of survival curves 
of the treatment groups was done using the log-rank 
test. Two-sided Fisher’s exact test was used for ana-
lyzing comparison of frequencies for qualitative data.
RESULTS AND DISCUSSION
First of all the frequency of LOH in genes from the 
OMIM (Online Mendelian Inheritance in Man) database 
was studied (http://omim.org/). A total of 13,815 genes 
were evaluated for heterozygosity loss in tumors of BC pa-
tients. The frequency of LOH varied from 0% to 63% for 
certain genes, thus 63% of patients showed LOH in some 
genes. The LOH frequency for 13,815 genes annotated 
in the OMIM database is presented in Fig. 1. In accor-
dance with the localization of genes on the chromosomes, 
they are plotted on the abscissa, and the percentage 
of patients with the LOH in the certain gene is depicted 
on the ordinate. Fig. 1 clearly shows that the highest 
incidence of the LOH events is characteristic for genes 
on chromosomes 17 and X.
The highest LOH frequency (from 30 to 63%) was 
observed in loci of ZNF267, PAGE3, MAGEH1, RRAGB, 
KLF8, UBQLN2, SPIN2B, SPIN2A, FAAH2, ZXDB, ZXDA, 
ARHGEF9, FAM123B, MSN, MIR223, VSIG4, HEPH, 
EDA2R, AR, SLC16A2, RLIM, KIAA2022, ABCB7, UPRT, 
ZDHHC15, MAGEE2, and MAGEE1 genes. It is impor-
tant to test the functional significance of these genes 
as tumor suppressors. In concordance with the infor-
mation of the OMIM database, chromosomes 6, 7, 
11 and 14 possess large regions, where the LOH was 
not observed in any of the 68 BC samples examined. 
In total, no LOH was detected in 873 out of 13,815 genes, 
annotated in the OMIM database. Well-known tumor 
suppressor genes, such as TP53, RB1, BRCA1 etc., 
also showed the low LOH frequency (Table 2).
Table 2. Frequency of LOH in known tumor suppressor genes
Tumor suppressor genes Frequency of LOH, n (%)
MEN1, TNFAIP3 0 (0.0)
CEBPA, JAK2, WRN 1 (0.7)
CDK6, CDKN2A, DCC, FBXW7, FOXP1, IL2, MSH2, 
PALB2, SOCS1, SYK
2 (1.4)
BCL11B, BMPR1A, CREB1, CREBBP, CYLD, IDH1, 
MDM4, NR4A3, PTEN, SDHB, STK11, SUFU, TCF3, 
TSC1, TSC2, VHL, WT1
3 (2.0)
APC, ATM, CDH11, EXT1, EXT2, NF2, RUNX1, SDHD, 
SMARCA4
4 (2.7)
CARS, CHEK2, FH, MLH1, NOTCH1, NPM1, NUP98, 
SMARCB1
5 (3.4)
BLM, BRCA2, CBFA2T3, PML, RB1 6 (4.1)
FLT3, MAP2K4 7 (4.8)
CDH1, SUZ12 8 (5.4)
CDKN2C, NF1, TP53 9 (6.1)
BRCA1 10 (6.8)
GPC3 11 (7.5)
DDX5 12 (8.2)
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The next step of investigation was to analyze the 
relationship between distant metastasis of breast tu-
mors and the LOH frequency in OMIM genes. Distant 
metastases occurred in 17 (25%) of the 68 patients 
within 10 to 77 months from the time of diagnosis. 
The two-, three- and five-year metastasis-free survival 
rates were 86.8; 82.4, and 76.5%, respectively.
The patients were divided into two groups: the first 
group consisted of 17 patients with metastases and 
the second group consisted of 51 patients without 
metastases.
Based on a difference between the frequency of the 
normal status of the gene and the LOH in patients with 
metastases and without metastases, we have selected 
genes in which this difference reached the maximum 
value. In result of our study seven genes were selected, 
namely, FGD1, GNL3L, TRO, EDA2R, PGK1, TAF9B, 
and CYSLTR1 for those the difference ranged from 
25.5 to 35.3%.
The next step was to evaluate the association 
between the LOH and metastasizing, using a Fish-
er’s exact test. The association between the LOH and 
metastasizing was demonstrated only for 4 genes: 
EDA2R, PGK1, TAF9B, and CYSLTR1. Using the Ka-
plan — Meier survival analysis, we showed that the 
metastasis-free survival rate in patients with the LOH 
in these genes was significantly lower, compared with 
those observed in the group of patients, who had 
a normal status of these genes (Fig. 2).
It should be noted that all of the genes identi-
fied in the study were located on the X chromosome 
(http://www.genecards.org/). EDA2R gene was lo-
calized on the long arm of the X chromosome (Xq12), 
while PGK1, TAF9B, and CYSLTR1 genes were loca-
lized in Xq21.1.
Deletions with LOH can provide a decrease 
in the expression of genes with LOH at the expense 
of to gene deficiency. Amplification with LOH results 
in an increase in gene expression. The copy-neutral 
LOH (cnLOH) may increase or decrease the expres-
sion of the gene with cnLOH. cnLOH might confer 
a phenotypic advantage for tumor cells due to gain 
of imprinting through duplication of a methylated allele 
(decrease the expression of the gene with cnLOH), 
loss of imprinting through duplication of unmethylated 
allele (increase the expression of the gene) or ho-
mozygosity of an initial heterozygous mutation [22]. 
The expression of genes with LOH it was necessary 
to explore in order to understand the impact of LOH 
on gene expression.
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Fig. 2. Metastasis-free survival of BC patients with the detected LOH in a set of genes: (a) Ectodysplasin A2 Receptor (EDA2R) 
gene; (b) phosphoglycerate kinase 1 (PGK1) gene; (c) RNA polymerase II, TATA Box-Binding Protein-Associated Factor (TAF9B) 
gene; (d) cysteinyl leukotriene receptor 1 (CYSLTR1) gene.
Note: a red line — patients with the LOH in genes examined; a blue line — patients with the normal status of genes examined. p — 
a significance value, calculated by a log-rank test
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In the study Ching et al. [23] was to explicate the 
underlying chromosomal copy number alterations 
and LOH implicated in a cohort of Malaysian hospital-
based primary breast carcinoma samples (n = 70) 
using a SNP-array platform. The most prevalent 
gains (≥ 30%) were detected at the 8q arm, whilst the 
most ubiquitous losses (≥ 20%) were noted at the 8p 
and 17p regions. The frequency of deletion with LOH 
of PGK1, TAF9B, and CYSLTR1 genes were 10%. 
cnLOH was characterized as the most prevailing 
LOH event, in which the most frequent distributions 
(≥ 30%) were revealed at 3p21.31, 5q33.2, 12q24.12, 
12q24.12-q24.13, and 14q23.1. The frequency 
of cnLOH EDA2R gene (ectodysplasin A2 receptor) 
was 24%, which along with TNFR1 and Fas (CD95) 
is one of the receptors of death. Yan et al. [24] showed 
that EDA2R gene appeared to activate expression 
of tumor necrosis factor gene. Studies suggest that 
EDA2R is a potential downstream effector of p53-
induced apoptosis in cancer cells [25, 26] and may 
therefore be a potential tumor suppressor, it is down-
regulated in breast and colorectal cancers [27, 
28], and mutations and promoter hypermethylation 
of EDA2R have been identified in colorectal cancer 
cells [25, 26]. A recent study conducted in 2016 us-
ing a microarray CytoScan HD Arraу showed that the 
presence of cnLOH in EDA2R gene and in several other 
genes was associated with ameloblastoma cases [29].
The protein encoded by PGK1 gene is a glycolytic 
enzyme that catalyzes the conversion of 1,3-diphos-
phoglycerate to 3-phosphoglycerate. Additionally, this 
protein is secreted by tumor cells where it participates 
in angiogenesis by functioning to reduce disulfide 
bonds in the serine protease, plasmin, which conse-
quently leads to the release of the tumor blood vessel 
inhibitor angiostatin (http://www.genecards.org/cgi-bin/ 
carddisp.pl?gene=PGK1&keywords=PGK1). CpG-island 
methylation was evaluated on a 56-gene cancer-specific 
biomarker microarray in metastatic vs non-metastatic 
BC in a multi-institutional case series of 123 BC patients. 
This identified 11 genes (including the PGK1 signaling 
kinase gene) as the highest differentially methy lated 
genes between progressing and non-progressing 
BC [30]. The PGK1 gene showed differential splicing 
in TNBC, non-TNBC (luminal A and B) and HER2-positive 
BC subtypes [31].
The TAF9B (TATA-Box Binding Protein Associated 
Factor 9b) is involved in transcriptional activation 
as well as repression of distinct but overlapping sets 
of genes. Among it related pathways is RNA Poly-
merase II transcription initiation. Microarray screen-
ing identified a TAF9B gene whose expression was 
significantly changed by combination treatment with 
inhibitors of LSD1 and HDAC of human BC cells [32]. 
Collectively, p53, SNHG1, sno-miR-28, and TAF9B 
form a regulatory loop which affects p53 stability and 
downstream p53-regulated pathways [33].
CYSLTR1 (Cysteinyl Leukotriene Receptor 1) is in-
volved in mediating bronchoconstriction via activation 
of a phosphatidylinositol-calcium second messenger 
system. Upregulation of this gene is associated with 
asthma and dysregulation may also be implicated 
in cancer. Patients with breast tumors characterized 
by high CysLT1R and low CysLT2R expression levels 
exhibited increased risk of cancer-induced death 
in univariate analysis for both the total patient group 
(hazard ratio [HR] = 2.88, 95% confidence interval 
[CI] = 1.11–7.41) [34].
Thus, the presence of LOH in EDA2R, PGK1, 
TAF9B, and CYSLTR1 genes were shown to be as-
sociated with low metastasis-free survival in patients 
with BC, indicating their potential value as prognostic 
markers.
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